. Author manuscript; available in PMC: 2014 Dec 11.

Published in final edited form as: Gynecol Oncol. 2009 Jun 13;114(3):431–436. doi: 10.1016/j.ygyno.2009.04.021

Table 5. Details of Immunohistochemistry and Patient Outcomes.

Patient No.	VEGF Score	Average MVD	Response to Bevacizumab	PFS (months)	Status	OS (months)
3	4	9.2	Partial response	25.5	AWD	25.5
4	6	12.4	Progression	5.5	AWD	37.3
6	1	9.4	Complete response	8.9	NED	8.5
7	6	10.2	Stable disease	1.6	DOD	9.4
8	6	21	Progression	1.7	DOD	28.9